Jim Cramer says that when it comes to alarming negativity and ridiculous exuberance, both extremes are wrong; investors need to get real.
The nutritional supplements company on Monday unveiled a deal to sell to private equity firm HGGC in a transaction valued at about $446M, including debt to be refinanced.
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
They are the stocks that are key to this market.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.